Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the FDA deciding on US approval by Nov. 14.
Michelle Xia, Akeso CEO
June 26, 2026 11:33 AM EDT
R&DChina
Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug
Max Gelman
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's…
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical…
Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung…
